Verona to test COPD hopeful ensifentrine in COVID-19 patients

Verona Pharma is starting a pilot study of its inhaled respiratory diseases drug ensifentrine in patients hospitalised with COVID-19.

The Anglo-American biotech is already developing ensifentrine in chronic obstructive pulmonary disease (COPD), but the company believes it could also help to relieve respiratory symptoms associated with viruses such as SARS-CoV-2.